Normotensive Primary Aldosteronism – Does it Exist?

Abstract

Heightened aldosterone levels are associated with increased risk of renal sequelae, cardiovascular morbidity and mortality. Historically, primary aldosteronism is linked to hypertension. However, growing evidence reveals its presence even in normotensive individuals. This review consolidates data from diverse sources, delves into clinical studies of this underexplored condition, discusses the potential mechanisms, and provides a comprehensive and an up-to-date overview of the current state of knowledge. It highlights the evidence and understanding of normotensive primary aldosteronism, summarizes findings, and identifies opportunities for future research in this area. By addressing the clinical evidence, risk of hypertension development and possible mechanisms involved, this review aims to advance the understanding of this distinct form of primary aldosteronism and inspire further research in this emerging field.

Keywords

hyperaldosteronism - RAAS - normotension - aldosterone-producing cell cluster - subclinical hyperaldosteronism

Publikationsverlauf

Eingereicht: 24. Oktober 2024

Angenommen nach Revision: 23. Januar 2025

Artikel online veröffentlicht:
06. März 2025

• References

• 1 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896
• 2 Ferreira NS, Tostes RC, Paradis P. et al. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens 2021; 34: 15-27
• 3 Loh HH, Sukor N. Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?. J Hum Hypertens 2020; 34: 5-15
• 4 Loh HH, Sukor N. Primary aldosteronism and obstructive sleep apnea: what do we know thus far?. Front Endocrinol (Lausanne) 2022; 13: 976979
• 5 Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9: 459-469
• 6 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 7 Brooks RV, Felix-Davies D, Lee MR. et al. Hyperaldosteronism from adrenal carcinoma. Br Med J 1972; 1: 220-221
• 8 Ito Y, Takeda R, Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102
• 9 Medeau V, Moreau F, Trinquart L. et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol (Oxf) 2008; 69: 20-28
• 10 Baudrand R, Guarda FJ, Fardella C. et al. Continuum of renin-independent aldosteronism in normotension. Hypertension 2017; 69: 950-956
• 11 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 2020; 173: 10-20
• 12 Karashima S, Kometani M, Tsujiguchi H. et al. Prevalence of primary aldosteronism without hypertension in the general population: results in Shika study. Clin Exp Hypertens 2018; 40: 118-125
• 13 Vasan RS, Evans JC, Larson MG. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
• 14 Markou A, Pappa T, Kaltsas G. et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98: 1409-1416
• 15 Sukor N. Primary aldosteronism: from bench to bedside. Endocrine 2012; 41: 31-39
• 16 Brown JM, Robinson-Cohen C, Luque-Fernandez MA. et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med 2017; 167: 630-641
• 17 Nishimoto K, Nakagawa K, Li D. et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab 2010; 95: 2296-2305
• 18 Nanba K, Vaidya A, Williams GH. Age-related autonomous aldosteronism. Circulation 2017; 136: 347-355
• 19 Omata K, Anand SK, Hovelson DH. et al. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals. J Endocr Soc 2017; 1: 787-799
• 20 Lim JS, Rainey WE. The potential role of aldosterone-producing cell clusters in adrenal disease. Horm Metab Res 2020; 52: 427-434
• 21 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
• 22 Nishimoto K, Tomlins SA, Kuick R. et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci U S A 2015; 112: E4591-E4599
• 23 Iwahashi N, Umakoshi H, Seki T. et al. Characterization of aldosterone-producing cell cluster (APCC) at single-cell resolution. J Clin Endocrinol Metab 2022; 107: 2439-2448
• 24 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
• 25 Rossi E, Regolisti G, Negro A. et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902
• 26 Loh KC, Koay ES, Khaw MC. et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859
• 27 Nishikawa T, Omura M. Should primary aldosteronism be diagnosed among normotensive subjects during general health check-up and/or at general outpatient clinics?. Hypertens Res 2011; 34: 47-48
• 28 Yildirim Ayaz E, Dincer B, Mesci B. Effect of green tea on blood pressure in healthy individuals: a meta-analysis. Altern Ther Health Med 2023; 29: 66-73
• 29 Aronow WS. Reduction in dietary sodium improves blood pressure and reduces cardiovascular events and mortality. Ann Transl Med 2017; 5: 405
• 30 O'Donnell E, Floras JS, Harvey PJ. Estrogen status and the renin angiotensin aldosterone system. Am J Physiol Regul Integr Comp Physiol 2014; 307: R498-R500
• 31 Chidambaram M, Duncan JA, Lai VS. et al. Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 2002; 13: 446-452
• 32 Sealey JE, Itskovitz-Eldor J, Rubattu S. et al. Estradiol- and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab 1994; 79: 258-264
• 33 Gersh FL, O'Keefe JH, Lavie CJ. et al. The renin-angiotensin-aldosterone system in postmenopausal women: the promise of hormone therapy. Mayo Clin Proc 2021; 96: 3130-3141
• 34 Millatt LJ, Abdel-Rahman EM, Siragy HM. Angiotensin II and nitric oxide: a question of balance. Regul Pept 1999; 81: 1-10
• 35 Huang WC, Lin YH, Wu VC. et al. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. J Clin Hypertens (Greenwich) 2022; 24: 1194-1203
• 36 Chauhan K, Schachna E, Libianto R. et al. Screening for primary aldosteronism is underutilised in patients with chronic kidney disease. J Nephrol 2022; 35: 1667-1677
• 37 Sukor N, Gordon RD, Ku YK. et al. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009; 94: 2437-2445
• 38 Wu VC, Wang SM, Chang CH. et al. Long term outcome of aldosteronism after target treatments. Sci Rep 2016; 6: 32103
• 39 Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019; 285: 126-148